CRNX Crinetics Pharmaceuticals


Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

Crinetics Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders on June 22, 2021. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.

1.The election of two directors to serve as Class III directors for a three-year term to expire at the 2024 annual meeting of stockholders. The following two Class III directors were re-elected by the votes indicated:

ForWithheldBroker Non-Votes
Camille Bedrosian, M.D.25,859,4714,554,3513,205,675
Wendell Wierenga, Ph.D.30,379,916 33,9063,205,675

2.The ratification of the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The selection was ratified by the votes indicated:

ForAgainstAbstainBroker Non-Votes